Profile of:

Mike Nurmohamed

Michael Nurmohamed is professor of Rheumatology at the Amsterdam University Medical Center, Netherlands. His chair has a focus on cardiovascular comorbidities in rheumatic diseases. He is also Head of Rheumatology Research Dept. of Reade, Amsterdam, The Netherlands, where he also works as Rheumatologist and Clinical Research Scientist since 2000. In 2020 he was appointed as a board member of the Dutch Medicines Evaluation Board. His main scientific interests include cardiovascular co-morbidities in rheumatic diseases. He was the convenor of several EULAR Task Forces about Cardiovascular disease risk management in patients inflammatory joint disorders. Dr. Nurmohamed has conducted many phase I – IV clinical investgiations with biologicals/tsDMARDs, COXIBs/NSAIDs, and antithrombotic agents and in rheumatoid arthritis, Bechterew's disease and psoriatic arthritis. There remains a need for increasing awareness and early diagnosis of the spondylarthropathies and therefore some of my PhD students are working in this field. Furthermore, there is still an unmet need for increasing the awareness cardiovascular comorbidities in SpA patients. As cardiovascular diseases are of the most important comorbidities in ankylosing spondylitis, more attention for this topic is urgently required. Furthermore, implementation of cardiovascular risk management in our daily clinical practice is warranted to lessen the cardiovascular disease burden of our patients and thus improve outcome of the disease. Dr. Nurmohamed has (co)authored over 400 publications, is a regular reviewer for several international journals and an editorial board member of Annals of Rheumatic Diseases , Arthritis Research Therapy, Journal of Rheumatology, The Open Rheumatology Journal and PlosOne. He serves on several (international) boards of cardiovascular scientific societies.

Full name: Mike Nurmohamed

Current country: Netherlands

Membership level: Full

Type of membership: Member

Number of publications: 13

Changes in Tumor Necrosis Factor Inhibitor Drug Survival in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Over 15 Years (2023)

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study. (2023)

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study (2023)

Prevalence and Radiographic Progression of Hip Involvement in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors (2023)

The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study (2022)

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study (2022)

Favorable effects on the hemostatic system in ankylosing spondylitis patients treated with golimumab (2021)

Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial (2021)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results (2021)

Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review (2020)

Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period (2020)

Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis (2020)

Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease – the eye for a heart study (2020)